Пищевод Барретта

1. Spechler SJ. Barrett’s esophagus and esophageal carcinoma: pathogenesis, diagnosis, and therapy. Med Clin of North Am, 2002;86:

2. DeMeester S.R., DeMeester T.R., Columnar Mucosa and Intestinal Metaplasia Of Esopphagus, Fifty Years of Controversy, Annals of Surg, 2000; 231:

3. Tileston W. Peptic ulcer of the esophagus. Am J Med Sci, 1906; 132:240-261

4. Lyall A. Chronic Peptic Ulcer of the Esophagus: A Report of Eight Cases. Br J Surg 1937, 24:534-547.

5. Barrett N.R. Chronic peptic ulcer of the esophagus and esophagitis. B. J. Surg, 1950 :175-182.

6. Allison P., Johnston A. The oesophagus lined with gastric mucous membrane Thorax 1953; 8; 8-101

7. MoerschR., Ellis F., McDonaldJ.R. Pathologic changes occurring in severe reflux esophagitis. Surg Gynecol Obstet 1959; 108:476-484.

8. Bremner C.G., Lynch V.P., Ellis H.F. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68: 209-216.

9. Hayward J. The lower end of the esophagus. Thorax 1961; 16:36-41.

10. Pauli A., Trier J.S., Dalton M.D., Camp R.C., Loeb P., Goyal R.K. The histologic spectrum of Barrett’s esophagus. N Engl J Med 1976; 295: 476-80.

11. Haggitt R.C., Tryzelaar J., Ellis F.H., Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. Am J Clin Pathol 1978; 70: 1-5.

12. Skinner D.B., Walther B.C., Riddell R.H., Schmidt H, lascone C, DeMeester T.R. Barrett’s esophagus.Comparison of benign and malignant cases. Ann Surg 1983; 198: 554-65.

13. Reid B.J., Weinstein W.M. Barrett's esophagus and adenocarcinoma [review], Ann Rev Med 1987; 38: 477-492.

14. Spechler S.J., Zeroogian J.M., Antonioli DA, etal. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6

15. Clark G.W., Ireland A.P., Peters J.H., Chandrasoma P, DeMeester T.R., Bremner C.G. Short-segment Barrett's esophagus: a prevalent complication of gastroesophageal reflux disease with malignant potential. J Gastrointest Surg 1997; 1: 113-122.

16. Sampliner R E., Practice Parameters Committee of the American College of Gastroenterology. Updated Guidelines for the Diagnosis, Surveillance, and therapy of Barrett's esophagus. Am J Gastro 2002; 97:1888-1895

17. Phillips R.W., Wong R.K. Barrett's esophagus. Natural history, incidence, etiology, and complications [review], Gastroenterol Clin North Am 1991; 20: 791-816.

18. Cameron A.J. Epidemiology of columnar-lined esophagus and adenocarcinoma [review], Gastroenterol Clin North Am 1997; 26:487-494.

19. Eloubeidi M.A., Provenzale D.: Does this patient have Barrett's Esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol 1999, 94:937-943.

20. Cameron A.J., Zinsmeister A.R., Ballard D.J., Carney J.A. Prevalence of columnar-lined (Barrett's) esophagus.Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-922.

21. Waring J.P., Barrett's esophagus: Current Concepts in diagnosis and Management. SAGES Annual Scientific Session & Postgraduate Course, March 29-April 1, 2000, Atlanta Georgia

22. Winters С., Spurting Т J., Chobanian S. J., Curtis D.J., Esposito R.L. Hacker J.F, etal. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.

23. Pera М., Cameron A.J., Trastek V.F., Carpenter H.A., Zinsmeister A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.

24. Lagergren J., Bergstrum R., Lindgren A., Nymn 0. Symptomatic gastroesophageal reflux disease as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.

25. Heitmiller R.F, Sharma R.Comparison of incidence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg 1996; 112:130-6.

26. Sarr M.G., Hamilton S.R., Marrone G.C., Cameron J.L. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with gastroesophageal reflux. Am J Surg 1985;149:187-93.

27. O'Connor J.B., Falk G.W., Richter J.E.: The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus. Am J Gastroenterol 1999, 94:2037-2042.

28. Blot W.J., Devesa S.S., Fraumeni J.F. Continuing climb in rates of esophageal adenocarcinoma: an update [letter]. JAMA 1993:270:1320

29. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni Jr. J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.

30. Devesa SS, Blot W.J., Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;15(83):2049-53.

31. Thomas R.J.S., LadeS., Giles G.G.,ThursfieldV. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust N Z J Surg 1996;66:271-5.

32. Armstrong R.W., Borman B. Trends in incidence rates of adenocarcinoma of the esophagus and gastric cardia in New Zealand, 1978-1992.Int J Epidemiol 1996;25:941-7.

33. Bytzer P., Christensen P.B., Damkier P., etal. Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.

34. Conio М., Cameron A.J., Romero Y., Branch C.D., Schleck C.D., Burgart L.J., et al. Secular trend in the epidemiology and outcome of Barrett’s esophagus in Olmsted County, Minnesota. Gut 2001; 48:304-9.

35. LordR.V.N., FrommerD.J., lnderS.,Tran D., Ward R.L. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's esophagus or Barrett's adenocarcinoma. Aust NZ J Surg 2000;70:26-33.

36. Armstrong R.W., Borman B. Trends in incidence rates of adenocarcinoma of the esophagus and gastric cardia in New Zealand, 1978-1992.Int J Epidemiol 1996;25:941-7.

37. BotterweckA.A.M., Schouten L.J., Volvics A., Dorant E., van den Brandt P.A. Trends in incidence of adenocarcinoma of the esophagus and gastric cardia in ten European countries.Int J Epidemiol 2000;29:645-54.

38. Hansen S., Wiig J.N., Giercksky K.E., Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites.Int J Cancer 1997;71:340-4.

39. Levi F., Randimibison L. , Lucchini F., Те V.C., La Vecchia C. Epidemiology of adenocarcinoma and squamous cell carcinoma of the esophagus. Eur J Cancer Prev 2001; 10:91-6.

40. McKinney P.A., Sharp L., Macfarlane G.J., Muir C.S. Esophageal and gastric cancer in Scotland 1960-90. Br. J. Cancer 1995;71:411 -5.

41. ChowW.H., Blot W.J., Vaughan T.L., Risch H.A., Gammon M.D., Stanford J.L., et al. Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.

42. El-Serag H.B., Mason A.C., Key C.R., Petersen N. Epidemiological difference between adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia. Gut 2002;50:368-72.

43. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni Jr. J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.

44. Devesa S.S., Blot W.J., Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;15(83):2049-53.

45. Hashem B. El-Serag, The epidemic of esophageal adenocarcinoma, Hematology/oncology Clinics of North America, 2003, 17(2).

46. Isolauri J., Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population. Ann Med 1995;27:67-70.

47. Locke III G.R., Talley N.J., Fett S.L., Zinsmeister A.R., Melton III L.J. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9.

48. Ruth М., Mansson I., Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991;26:73-81.

49. Chow W.H., Blaser M.J., Blot W.J., Gammon M.D., Vaughan T.L., Risch H.A., et al. An inverse relationship between cagA* strains of Helicobacter pylori infection and the risk of esophageal and gastric cardia combined. Cancer Res 1998;58:588-90.

50. Hansson L.E., Engstrand L., Nymn O., Lindgren A. Prevalence of Helicobacter pylori in subtypes of gastric cancer. Gastroenterology 1995;109:885-8.

51. Lord RVN, Frommer D.J., Inder S., Tran D., Ward R.L. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's esophagus or Barrett's adenocarcinoma. Aust NZ J Surg 2000;70:26-33.

52. Vaughan T.L., Farrow D.C., Hansten P.D., Chow W.H., Gammon M.D., Risch H.A., etal. Risk of esophageal and gastric adenocarcinoma in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749-56.

53. Vicari J.J , Peek R.M., Falk G.W., Goldblum J R., Easley K.A., Schnell J., et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.

54. Suleiman U.L., Harrison М., Britton A., McPherson K., Bates T H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000;9:185-91.

55. El-Omar E.M., Penman I.D., Ardill J.E., Chittajallu R.S., Howie C., McColl KEL Helicobacter pylori infection in patients with duodenal ulcer disease. Gastroenterology 1995:109:681-91.

56. Graham D.Y., Yamakoa Y. H. pylori and CagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.

57. El-Serag H.B., Sonnenberg A., Jamal М.М., Inadomi J.M., Crooks L, Feddersen R. Corpus gastritis is protective against reflux esophagitis. Gut 1999;45:181-5.

58. Gutierrez O., Melo М., Segura A.M., Angel A., Genta R.M., Graham D.Y. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.

59. Romero Y., Cameron A.J., Locke III G.R., Schaid D.J., Slezak J.M., Branch C.D., et al. Familial aggregation of gastroesophageal reflux in patients with Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113:1449-56

60. Hu F.Z., Preston R.A., Post J.C., White G.J., Kikuchi L.W., Wang X., etal. Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q 14. JAMA 2000;284:325-34.

61. World Health Organization. The international classification of diseases. 9th revision. Clinical modification, 2nd edition Washington, DC: Public Health Service, US Government Printing Office; 1980. DHHS Publication No. (PHS) 80-1260.

62. Terry P., Lagergren J., Weimin Y., Nyriin O., Wolk A. Antioxidants and cancers of the esophagus and gastric cardia.Int J Cancer 2000;87:750-4.

63. Gray J R., Coldman A.J., Mac Donald WC. Cigarette and alcohol use in patients with adenocarcinoma of the gastric cardia or lower esophagus. Cancer 1992;69:2227-31.

64. Gammon M.D., Schoenberg J.B., Ahsan H., Risch H.A., Vaughan T.L., Chow W.H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:1277-84.

65. Lagergren J., Bergstrum R., Lindgren A., Nyriin O. The role of tobacco, snuff and alcohol use in the etiology of cancer of the esophagus and gastric cardia.Int J Cancer 2000;85:340-6.

66. Lagergren J., Bergstrum R., Lindgren A., Adami H.O., Nyriin O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000:133:165-75.

67. Vaughan T.L., Davis S., Kristal A., Thomas D.B. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.

68. Lieberman D.A., Oehlke M., Helfand M. GORGE Consortium. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997;92:1293-7.

69. Hirota W.K. Lougney T.M., Lazas D.J., Maydonovitch C.L., Rholl V, Wong R.K.H. Specialized Intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data, Gastroenterology 116:2-285, 199.

70. Eisen G.M., Sandler R.S., Murray S:, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92: 27-31.

71. Clark G.W., Ireland A.P., DeMeester T.R. Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment [review]. Dig Dis 1996; 14: 213-27.

72. Stein H.J., Hoeft S., DeMeester T.R. Functional foregut abnormalities in Barrett’s esophagus. J Thorac Cardiovasc Surg 1993; 105: 107-111.

73. Singh P., Taylor R.H., Colin-Jones D.G. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994; 89: 349-356.

74. Meyer W., Vollmar F., Bar W. Barrett-esophagus following total gastrectomy. A contribution to its pathogenesis. Endoscopy 1979; 11: 121-126.

75. Seto Y., Kobori O.: Role of reflux esophagitis and acid in the development of columnar epithelium in the rat oesophagus. Br J Surg 80:467-470, 1993.

76. Fein М., Ireland A.P., Ritter M.P., et al: The contribution of duodenogastric reflux to esophageal injury. Gastroenterology 110:A1383, 1996.

77. Oberg S., Ritter M.P., Crookes P.F., etal. Gastroesophageal reflux disease and mucosal injury with emphasis on short-segment Barrett's esophagus and duodenogastroesophageal reflux. J Gastrointest Surg 1998; 2: 547-554.

78. Fein М., Ireland A.P., Ritter M.P., et al. Duodenogastric reflux potentiates the injurious effects of gastroesophageal reflux. J Gastrointest Surg 1997; 1: 27-33.

79. Kuo B., Castell D.O. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 1532-1538.

80. Kauer W.K., Peters J.H., DeMeester T.R., Ireland A.P., Bremner C.G., Hagen J.A. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995; 222: 525-533.

81. Jankowski J.: Gene expression in Barrett's mucosa: modulation of acute and chronic adaptive respones. Gut 1993, 34:1012-1014.

82. Jankowski J., Austin W., Howat K., Coghill G., Dover R., Hopwood D., Wormsley K.: Proliferating cell nuclear antigen labelling in the oesophagus; correlation with autoradiography. Eur J Gastroenterol Hepatol 1992, 4:579-584.

83. Hanby A., Jankowski J., Elia G., Poulsom R., Wright N.A.: Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett’s metaplasia and the native oesophageal epithelium differentiates secretory lineages. J Pathol 1994, 168:210-216.

84. Jankowski J., Wright N.A.: Epithelial stem cells in the gastrointestinal tract: structure, function and adaptation. Sem Cell Biol 1992, 3:445-456.

85. Shields H.M., Sawhney R.A., Zwas F, Boch J.A., Kim S., Goran D., Antonioli D.A.: Scanning electron microscopy of the human esophagus: application to Barrett's esophagus, a precancerous lesion. Microsc Res Tech 1995, 31:248-256.

86. Boch J.A., Shields H.M., Antonioli D.A., Zwas F., Sawhney R.A., Trier JS: Distribution of cytokeratin markers in Barrett's specialised columnar epithelium. Gastroenterology 1997, 112:760-765.

87. Jankowski J.: Gene expression in Barrett's mucosa: modulation of acute and chronic adaptive respones. Gut 1993, 34:1012-1014.

88. Fitzgerald R.C., Omary M.B., Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120-2128.

89. Chandrasoma P. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg 1997; 9: 270-278.

90. DeMeester S.R., DeMeester T.R. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy , Ann Surg , 2000; 231(3): 303-21.

91. Csendes A., Maluenda F., Braghetto I., Csendes P, Henriquez A., Quesada MS. Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis. Gut 1993; 34: 21-27.

92. Cameron A.J., Lomboy C.T Barrett's esophagus: age, prevalence, andextentofcolumnarepithelium. Gastroenterology 1992; 103:1241-1245.

93. Krishnadath K.K., Tilanus H.W., van Blankenstein М., Bosman F.T., Mulder A.H. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995; 175: 175-180.

94. Menke-Pluymers M.B., Mulder A.H., Hop W.C., van Blankenstein М., Tilanus H.W. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994; 35: 1348-1351.

95. Rice T.W., Goldblum J.R., Falk G.W., Tubbs R.R., Kirby T.J., Casey G. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 1994; 108: 1132-1137.

96. Krishnadath K.K., Tilanus H.W., van Blankenstein М., et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 1995; 55: 1971-1976.

97. Bonavina L. Barrett's esophagus & cancer: What is the relationship? [Postgraduate Course II: Barrett's Esophagus]. Program and abstracts of the Society of American Gastrointestinal Endoscopic Surgeons Annual Scientific Session & Postgraduate Course; March 30, 2000; Atlanta, Georgia.